Copenhagen Bioengineering ApS: Financial statements 2022
CVR: 37640549
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Copenhagen Bioengineering ApS (CVR 37640549) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -484,135 and a net result of DKK -413,896 compared with DKK 158,190 the year before. Equity in the 2022 report amounted to DKK 915,126. The solvency ratio was 89.9%.
- Gross Profit
- DKK -484,135
- Profit/Loss
- DKK -413,896
- Equity
- DKK 915,126
- Total Assets
- DKK 1,017,920
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -484 t. | -414 t. | 915 t. | - |
| 2021 | - | 243 t. | 158 t. | 1.3 mio. | - |
| 2020 | - | 693 t. | 514 t. | 1.2 mio. | 0 |
| 2019 | - | 531 t. | 406 t. | 657 t. | 0 |
| 2018 | - | 262 t. | 202 t. | 250 t. | - |
Official annual report
Keep an eye on Copenhagen Bioengineering ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of August 15, 2022, Helge Anker Andreasen has left the board of directors of Copenhagen Bioengineering ApS.
As of August 15, 2022, Strukturforsyningen ApS is registered as an owner of Copenhagen Bioengineering ApS with an ownership share of 25%.
As of August 15, 2022, Holtug Holding ApS is registered as an owner of Copenhagen Bioengineering ApS with an ownership share of 25%.
As of August 15, 2022, P.F. Kaaber Holding ApS is registered as an owner of Copenhagen Bioengineering ApS with an ownership share of 25%.
Copenhagen Bioengineering ApS has published its annual report for 2021. Gross profit came to DKK 243,310, and the net result was DKK 158,190.
As of June 29, 2022, Dansk Revision Næstved Godkendt Revisionsaktieselskab has been appointed auditor of Copenhagen Bioengineering ApS.
As of June 29, 2022, Barrett revisionsanpartsselskab has stepped down as auditor of Copenhagen Bioengineering ApS.
As of May 1, 2022, Phillip Falkenløve Kaaber is registered as adm. dir. of Copenhagen Bioengineering ApS.
As of May 1, 2022, Marco Falkenløve Kaaber is registered as director of Copenhagen Bioengineering ApS.
As of May 1, 2022, Helge Anker Andreasen has stepped down as director of Copenhagen Bioengineering ApS.
About Copenhagen Bioengineering ApS
Copenhagen Bioengineering ApS is a Danish company of the type Anpartsselskab based in Hårlev, founded in 2016. The company is registered under the industry Leasing af intellektuelle ejendomsrettigheder og lignende produkter, dog ikke ophavsretsbeskyttede værker. The management consists of Phillip Falkenløve Kaaber and Marco Falkenløve Kaaber. The board consists of Niels Juul Jensen. The company's owners include Strukturforsyningen ApS, Holtug Holding ApS and M.F. Kaaber Holding ApS. The company has 1 employee (2025). In 2025, the company reported a gross profit of DKK -90,560 and a net result of DKK -210,012 compared with DKK 27,263 the year before. Equity in the 2025 report amounted to DKK 808,561.